←Cardiology & EP
HFrEF — reduced EF & the 4 pillars
📚
📚 Library › ❤️ Cardiology & EP › Heart failure
🏛️

HFrEF — reduced EF & the 4 pillars

EF ≤40%. Four drugs that save lives, how to start them, doses, devices and add-ons.

HFrEFGDMTARNISGLT2iICD
🗓️ Reviewed 2026-11-18 · ⏱️ 4 min read · 📖 2022 AHA/ACC/HFSA HF guideline · 2024 ACC ECDP HFrEF · 2026 Universal Definition of HF
🧠 Pathophysiology in 60 seconds🔎 Classification🧪 Workup — new cardiomyopathy💊 Management — the 4 pillars⚠️ Pitfalls🎓 Board corner📚 References
⚡ Bottom line — first hour
  • HFrEF = EF ≤40%. Four pillars: ARNI · β-blocker · MRA · SGLT2i. Together they cut mortality by ~60%.
  • Start all four early, even at low doses. Order matters less than speed.
  • Ischemic workup for every new cardiomyopathy.
  • ICD if EF ≤35% after ≥90 days of GDMT (≥40 days after MI). CRT if LBBB + QRS ≥150.
  • HFimpEF (EF improved >40%) → never stop GDMT.

🧠 Pathophysiology in 60 seconds

⌄
  • Injured myocardium (MI, toxins, genetic, myocarditis, tachycardia) → low stroke volume.
  • The body "defends" BP with RAAS + sympathetic drive + vasopressin → short-term help, long-term harm: fibrosis, remodeling, dilation.
  • Each pillar blocks a harmful neurohormone (ARNI, BB, MRA) or unloads the heart and kidney (SGLT2i).
HFrEFEF ≤40%4 pillars save lives
HFmrEFEF 41–49%SGLT2i; consider others
HFpEFEF ≥50%SGLT2i + finerenone
↗️ HFimpEF = EF was ≤40%, now >40% → keep GDMT. Stopping it lets EF fall again.
🛡️ARNIsacubitril/valsartan
(or ACEi/ARB)
🐢β-blockercarvedilol, metoprolol succinate, bisoprolol
🧲MRAspironolactone / eplerenone
🍬SGLT2idapagliflozin / empagliflozin
🏛️ Start all four early — low doses together beat one drug at max dose.

🔎 Classification

⌄
Scheme Levels
ACC/AHA stages A at risk · B structural disease, no symptoms · C symptoms · D advanced
NYHA class I none · II ordinary activity · III less than ordinary · IV at rest
EF HFrEF ≤40 · HFmrEF 41–49 · HFpEF ≥50 · HFimpEF (was ≤40, now >40)
🆕 2026 update

The Second Universal Definition of HF (June 2026) moves away from rigid EF cut-offs and stresses cause, trajectory and early detection. Treatment still follows the 2022 guideline until the new AHA/ACC guideline (expected 2027).

🧪 Workup — new cardiomyopathy

⌄

TTE · ECG · BNP · BMP, CBC, TSH, iron, A1c, lipids, HIV/hepatitis (selected), ischemic evaluation (cath or CCTA) · cardiac MRI (myocarditis, sarcoid, amyloid, LV thrombus) · alcohol, cocaine, chemo history · genetic testing if family history.

💊 Management — the 4 pillars

⌄
Drug Start Target Watch
Sacubitril/valsartan 24/26 mg BID (49/51 if on ACEi/ARB) 97/103 mg BID 36 h washout after ACEi; BP, K, Cr; angioedema
Carvedilol 3.125 mg BID 25 mg BID (50 if >85 kg) Not in decompensation/shock
Metoprolol succinate 12.5–25 mg daily 200 mg daily Only succinate (not tartrate) has HF data
Spironolactone 12.5–25 mg daily 25–50 mg daily K <5.0, eGFR >30; gynecomastia → eplerenone
Dapagliflozin / empagliflozin 10 mg daily 10 mg daily Genital infection; hold if NPO/sick (euglycemic DKA)
💡 Pearl

Soft BP? Start SGLT2i and MRA first (little BP effect), then low-dose BB and ARNI. A small Cr rise (≤30%) after ARNI/MRA/SGLT2i is expected — do not stop.

  • Hydralazine + isosorbide dinitrate — self-identified Black patients, NYHA III–IV on GDMT (A-HeFT); or anyone who cannot take ARNI/ACEi/ARB.
  • Ivabradine — sinus rhythm, HR ≥70 on max-tolerated BB.
  • Vericiguat — recent worsening HF.
  • Digoxin — persistent symptoms; target level 0.5–0.9.
  • IV iron (ferric carboxymaltose / derisomaltose) — ferritin <100, or 100–299 + TSAT <20%.
  • Loop diuretic — for congestion only (symptoms, not survival).
  • ICD (primary prevention): EF ≤35%, NYHA II–III, ≥90 days GDMT, ≥40 days post-MI, life expectancy >1 year.
  • CRT: EF ≤35%, sinus, LBBB with QRS ≥150 ms (strongest benefit).
  • TEER (MitraClip): severe secondary MR despite GDMT (COAPT).
  • LifeVest — bridge in selected new cardiomyopathy.
  • Non-DHP CCB (diltiazem, verapamil) · NSAIDs · TZDs (pioglitazone) · dronedarone · most antiarrhythmics except amiodarone/dofetilide · saxagliptin.

⚠️ Pitfalls

⌄
  • One drug titrated to max while others never start.
  • Stopping BB in stable patients for mild hypotension or fatigue.
  • Forgetting the 36-hour ACEi → ARNI washout.
  • Stopping GDMT when EF recovers (TRED-HF: relapse).

🎓 Board corner

⌄
Stem Answer
EF 30%, on lisinopril, switch to ARNI Stop ACEi, wait 36 h
EF 30% on GDMT, NYHA II, QRS 160 LBBB CRT-D
Which BB is NOT HFrEF evidence-based? Metoprolol tartrate, atenolol
Black patient, NYHA III on full GDMT Add hydralazine–ISDN
HFrEF + gout → NSAID? Avoid NSAIDs
EF improved 30% → 50% on GDMT Continue all GDMT

📚 References

⌄
  • Heidenreich PA, et al. 2022 AHA/ACC/HFSA HF guideline. Circulation. 2022;145:e895.
  • Maddox TM, et al. 2024 ACC ECDP for HFrEF. J Am Coll Cardiol. 2024;83:1444.
  • PARADIGM-HF · DAPA-HF · EMPEROR-Reduced · RALES · COPERNICUS · A-HeFT · TRED-HF.
  • Second Universal Definition of Heart Failure. Circulation / JACC. June 2026.
↩︎ Back to ❤️ Cardiology & EP